PR99016

PARIS, Nov. 29, 2022 /PRNewswire=KYODO JBN/ --

TargEDys and SymbioPharm signed an exclusive marketing and distribution

agreement for the launch of SymbioLife(R) Satylia(R) in Germany. The novel

dietary supplement based on the next-generation probiotic Hafnia alvei HA4597

will be available from January 2023.

SymbioLife(R) Satylia(R) is a precision probiotic with a characterized

mechanism of action at molecular level: it increases satiety thanks to the

protein ClpB produced by Hafnia alvei HA4597. ClpB naturally mimics the human

satiety hormone alpha-MSH. The improved feeling of satiety helps with

successful weight loss, as confirmed by a clinical study with 230 overweight

adults. This natural principle provided by SymbioLife(R) Satylia(R) is a

multi-awarded new, natural, safe and effective weight management solution.

Gregory Lambert, CEO of TargEDys: "We are extremely proud and excited about

this new collaboration. SymbioPharm is in the top 3 of the German probiotics

market and fathered one of the first probiotic pharmaceuticals globally. With

the team's knowledge of probiotic Enterobacteria, their strong position with

doctors, pharmacies, and synergies with probiotics and diagnostics, they are

the perfect partner for this highly scientific product."

Juergen Eck, Co-CEO and CTO of SymbioPharm:

"We are very excited to partner with TargEDys and work together on a new era of

evidence-based probiotics. With the patent-protected probiotic Hafnia alvei

HA4597, its biological mechanism of action and outstanding studies, we can

offer an effective solution for the growing problems of obesity and metabolic

health. As pioneers in microbiome research and medical probiotics, we are proud

to now also help shape the introduction of knowledge-based precision

probiotics."

About SymbioPharm

SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based

probiotics - since 1954. Its mission is to preserve health and to heal diseases

with probiotic bacteria – making use of purely biological effect of natural

bacteria. Therefore, it researches the human microbiome and develops innovative

microbiological therapy approaches. The company holds a state-of-the-art

production facility, and showcases comprehensive expertise from diagnostics –

with the Institute for Microecology – to innovative solutions.

www.symbiopharm.de

About TargEDys(R)

TargEDys(R) is a commercial-stage French biotech specialized in the development

of nutraceutical solutions through microbiome interventions. The company is

based on 15 years of research on the microbiota conducted within academic

laboratories. TargEDys(R)' portfolio focuses on overweight, undernutrition, and

mental health, all based on the concept of PreciBiomic strains backed by a

molecular mechanism of action and in vivo studies.

www.targedys.com

Contact:  

Arnaud Faure & Nina Vinot

bd@targedys.com

Logo - https://mma.prnewswire.com/media/1956913/TargEDys_SymbioPharm_Logo.jpg

SOURCE: TargEDys